Black Diamond Therapeutics (BDTX) Operating Income: 2018-2021
Historic Operating Income for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$126.9 million.
- Black Diamond Therapeutics' Operating Income fell 12.50% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.3 million, marking a year-over-year decrease of 65.79%. This contributed to the annual value of -$126.9 million for FY2021, which is 82.37% down from last year.
- According to the latest figures from FY2021, Black Diamond Therapeutics' Operating Income is -$126.9 million, which was down 82.37% from -$69.6 million recorded in FY2020.
- In the past 5 years, Black Diamond Therapeutics' Operating Income registered a high of -$8.9 million during FY2018, and its lowest value of -$126.9 million during FY2021.
- Moreover, its 3-year median value for Operating Income was -$69.6 million (2020), whereas its average is -$75.3 million.
- Data for Black Diamond Therapeutics' Operating Income shows a maximum YoY plummeted of 229.42% (in 2019) over the last 5 years.
- Yearly analysis of 4 years shows Black Diamond Therapeutics' Operating Income stood at -$8.9 million in 2018, then tumbled by 229.42% to -$29.3 million in 2019, then crashed by 137.18% to -$69.6 million in 2020, then plummeted by 82.37% to -$126.9 million in 2021.